Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have been assigned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $19.00.

Several analysts have issued reports on ABEO shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Thursday, March 19th. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Stifel Nicolaus set a $17.00 price target on Abeona Therapeutics in a research note on Tuesday, March 17th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st.

Abeona Therapeutics Stock Performance

ABEO opened at $5.90 on Monday. The business’s 50-day moving average price is $5.02 and its two-hundred day moving average price is $5.03. Abeona Therapeutics has a 1 year low of $4.00 and a 1 year high of $7.54. The company has a market capitalization of $335.59 million, a price-to-earnings ratio of 5.73 and a beta of 1.35. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.93 and a quick ratio of 6.74.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $5.65 million. Equities analysts expect that Abeona Therapeutics will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Abeona Therapeutics

Hedge funds have recently modified their holdings of the stock. Aberdeen Group plc bought a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $3,248,000. AIGH Capital Management LLC bought a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $10,540,000. Nan Fung Trinity HK Ltd. grew its holdings in shares of Abeona Therapeutics by 70.6% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 956,770 shares of the biopharmaceutical company’s stock valued at $5,042,000 after acquiring an additional 396,000 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $57,000. Finally, Riverwater Partners LLC grew its holdings in shares of Abeona Therapeutics by 45.6% in the 3rd quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 4,963 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.